8-K: Marinus Pharmaceuticals Provides Update on RAISE Trial and Reports Preliminary Q1 2024 Financials

Marinus Pharmaceuticals announced the RAISE trial did not meet interim stopping criteria, completed enrollment, and reported preliminary Q1 2024 revenue between $7.4 and $7.6 million.

Summary

• Marinus Pharmaceuticals announced that the Phase 3 RAISE trial for IV ganaxolone in refractory status epilepticus did not meet pre-defined stopping criteria at the interim analysis.
• The company has completed enrollment in the RAISE trial with approximately 100 patients, and topline results are expected in the summer of 2024.
• The future development of IV ganaxolone will be assessed after reviewing the final RAISE results.
• Enrollment in the TrustTSC trial is expected to be completed in mid-May, with topline data expected in the first half of Q4 2024.
• Marinus reported preliminary net product revenue for ZTALMY in Q1 2024 between $7.4 and $7.6 million.
• The company's preliminary unaudited cash, cash equivalents, and short-term investments were $113.3 million as of March 31, 2024.
• Cost reduction activities are under review and expected to be implemented in Q2 2024 to extend the cash runway.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the RAISE trial not meeting its interim stopping criteria and the need for cost reduction activities, although there are some positives such as revenue and cash position.

Positives

• The company has completed enrollment in the RAISE trial, which will provide data to determine the future of IV ganaxolone development.
• The TrustTSC trial is progressing with enrollment expected to complete in mid-May and topline data expected in the first half of Q4 2024.
• ZTALMY generated preliminary net product revenue between $7.4 and $7.6 million in Q1 2024.
• Marinus has a cash position of $113.3 million as of March 31, 2024.
• The company is actively reviewing cost reduction activities to extend its cash runway.

Negatives

• The RAISE trial did not meet its pre-defined stopping criteria at the interim analysis, indicating a potential setback in the development of IV ganaxolone.
• The future development of IV ganaxolone is uncertain and dependent on the final RAISE trial results.
• The company is implementing cost reduction activities, which may indicate financial pressures.

Risks

• The future of IV ganaxolone development is uncertain and dependent on the final results of the RAISE trial.
• The company's cash runway may be limited, necessitating cost reduction activities.
• There are risks associated with the commercialization of ZTALMY, including market acceptance and payor coverage.
• Clinical trial results may not support regulatory approval or further development.
• The company faces competition and potential adverse events or patient outcomes from being treated with ZTALMY.

Future Outlook

The company plans to assess the future development of IV ganaxolone after reviewing the final RAISE trial results, complete enrollment in the TrustTSC trial, and implement cost reduction activities to extend the cash runway. They also plan to file a supplemental New Drug Application to the FDA in the first half of 2025.

Management Comments

• Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus, stated that while they are disappointed that RAISE did not meet the early stopping criteria, they will only be able to determine the trial's outcome once they unblind and analyze the full data set.
• Management also mentioned they will be evaluating potential cost-saving strategies to provide the strongest capital position as they approach enrollment completion in the global Phase 3 TrustTSC trial.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies focused on developing treatments for seizure disorders. The results of the RAISE trial and the progress of the TrustTSC trial are important for Marinus's competitive position in the market. The company's financial update also provides insight into its commercial performance and cash position.

Comparison to Industry Standards

• Marinus's Q1 2024 revenue of $7.4 to $7.6 million is a key metric for a commercial-stage pharmaceutical company, and will be compared to other companies in the space such as Zogenix (acquired by UCB) which had similar products in development.
• The cash position of $113.3 million is a critical factor in assessing the company's ability to fund ongoing clinical trials and commercial operations, and will be compared to other companies of similar size and stage.
• The RAISE trial is a Phase 3 trial, and the results will be compared to other similar trials in the refractory status epilepticus space, such as those conducted by companies like UCB and Eisai.
• The TrustTSC trial is a Phase 3 trial, and the results will be compared to other similar trials in the tuberous sclerosis complex space, such as those conducted by companies like Novartis.

Stakeholder Impact

• Shareholders may be concerned about the RAISE trial results and the need for cost reduction activities.
• Employees may be affected by the cost reduction activities.
• Patients and physicians are awaiting the results of the RAISE and TrustTSC trials to determine the potential of ganaxolone as a treatment option.
• Suppliers and creditors may be impacted by the company's cost reduction activities.

Next Steps

• Marinus will review the final results of the RAISE trial to determine the future of IV ganaxolone development.
• The company will complete enrollment in the TrustTSC trial in mid-May.
• Topline data from the TrustTSC trial is expected in the first half of Q4 2024.
• Marinus plans to implement cost reduction activities in Q2 2024.
• The company anticipates filing a supplemental New Drug Application to the FDA in the first half of 2025 for the TrustTSC trial.

Key Dates

Keywords

ganaxolone, ZTALMY, RAISE trial, TrustTSC trial, refractory status epilepticus, tuberous sclerosis complex, clinical trials, pharmaceutical, seizure disorders, net product revenue, cash runway